<DOC>
	<DOCNO>NCT00012259</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness troxacitabine treat patient blast phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Troxacitabine Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , term achieve complete hematologic remission , partial hematologic remission , hematologic improvement , partial response , back chronic phase status , patient blastic phase chronic myelogenous leukemia treat troxacitabine . II . Determine proportion patient whose disease return chronic phase remain level least 3 month treat drug . III . Determine toxicity profile drug patient . IV . Determine duration survival patient treated drug . OUTLINE : This multicenter study . Patients receive troxacitabine IV 30 minute day 1-5 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 4 week relapse . PROJECTED ACCRUAL : A maximum 50 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Troxacitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Philadelphia chromosomepositive blastic phase chronic myelogenous leukemia ( CML ) blast nonlymphoid origin Blastic phase define : At least 30 % blast blood bone marrow OR Presence extramedullary infiltration outside liver spleen No leukemic CNS involvement PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL AST ALT less 3 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine le 1.8 mg/dL creatinine clearance least 45 mL/min Other : No known hypersensitivity troxacitabine analogues No active uncontrolled serious infection No severe medical condition would preclude study No neurologic psychiatric disorder would preclude informed consent No uncontrolled underlie medical condition underlie condition could aggrevated treatment Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 24 hour since prior hydroxyurea Prior STI571 blastic phase chronic myelogenous leukemia allow No prior chemotherapy blastic phase disease Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 14 day since prior investigational agent recover No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>